SAGE Stock Recent News
SAGE LATEST HEADLINES
LOS ANGELES , Oct. 22, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ: SAGE).
NEW YORK, NY / ACCESSWIRE / October 22, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sage-therapeutics-lawsuit-submission-form?prid=109310&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / October 22, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sage-therapeutics-lawsuit-submission-form?prid=109296&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sage Therapeutics, Inc. (NASDAQ: SAGE) between April 12, 2021 and July 23, 2024, both dates inclusive (the “Class Period”), of the important October 28, 2024 lead plaintiff deadline.
NEW YORK, NY / ACCESSWIRE / October 22, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sage-therapeutics-lawsuit-submission-form?prid=109280&wire=1 or contact Joseph E. Levi, Esq.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Sage To Contact Him Directly To Discuss Their Options NEW YORK CITY, NY / ACCESSWIRE / October 22, 2024 / If you suffered losses exceeding $75,000 in Sage between April 12, 2021 and July 23, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ:SAGE) and reminds investors of the October 28, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
NEW YORK, NY / ACCESSWIRE / October 22, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sage-therapeutics-lawsuit-submission-form?prid=109263&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / October 22, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sage-therapeutics-lawsuit-submission-form?prid=109251&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sage Therapeutics, Inc. (“Sage” or “the Company”) (NASDAQ: SAGE) and certain of its officers.
NEW YORK, NY / ACCESSWIRE / October 22, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sage-therapeutics-lawsuit-submission-form?prid=109206&wire=1 or contact Joseph E. Levi, Esq.